Benzinga | Oct 27, 2020 05:08AM EDT

Chardan Capital Initiates Coverage On Axcella Health with Buy Rating, Announces Price Target of $16

Chardan Capital analyst Michael Morabito initiates coverage on Axcella Health (NASDAQ:AXLA) with a Buy rating and announces Price Target of $16.